The Lymphotoxin-Interferon Antiviral Immunity Axis
Over the last 15 years our lab has been studying the link between lymphotoxins (LT) and the regulation of type
CMV Targets the Immune Checkpoint Inhibitor BTLA
Virulent isolates of CMV encode the ul144 orf, and we identified UL144 as an orthologue of the herpesvirus entry mediator
T Cell Immunity and CMV
HCMV-specific CD8 T cells protect bone marrow transplant patients when used in cellular immunotherapy, and their long-term maintenance is enhanced
CMV Interfaces with The Trail Cytokine System
We have recently discovered a novel connection between the TNF-related apoptosis inducing ligand (TRAIL) cytokine system and CMV. TRAIL is
Benedict Lab
Christopher Benedict,
Ph.D.
Associate Professor
Center for Autoimmunity and Inflammation, Center for Vaccine Innovation
Christopher Benedict, Ph.D., studies the strategies that viruses use to escape detection by our immune system.
Q&A with Dr. Benedict
As a scientist Chris Benedict, Ph.D., came of age during the heyday of gene therapy. But when the first clinical
Researchers advance fight against leading infectious cause of congenital birth defects
SAN DIEGO – March 13, 2013 A virus most people probably have never heard of, but that the majority of
Chris Benedict
Institute Leadership Assistant Professor of Computational Biology, Additional title, another title.
